JRJeffrey J. Rade

Jeffrey J. Rade

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeffrey J. Rade has a total of 91 co-authors. Here are the top co-authors by number of shared publications:

  • Nikolaos Kakouros

    Division of Cardiovascular Medicine, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts

    5 shared publications
  • Bruce A. Barton

    Division of Biostatistics and Health Services Research, Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA

    3 shared publications
  • Nikolaos Kakouros

    Department of Medicine, UMass Chan Medical School

    3 shared publications
  • Thomas S. Kickler

    Department of Pathology, The Johns Hopkins School of Medicine, Baltimore, Maryland, USA

    3 shared publications
  • Essa Hariri

    University of Massachusetts Chan Medical School , Worcester, MA , United States

    2 shared publications
  • Katherine Laws

    Division of Cardiology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland

    2 shared publications

Latest Publications

  • Modifiable Correlates With Systemic Thromboxane Generation and Association With Cardiovascular Outcomes: Results From the Framingham Heart Study

    by Frank Qian, Priya Gajjar, Brenton Prescott, Gary F. Mitchell, Vanessa Xanthakis, Jeffrey J. Rade, Matthew Nayor

    BACKGROUND: Systemic thromboxane A 2 generation, assessed via measurement of its urinary metabolites, is associated with cardiovascular disease (CVD) risk. Modifiable correlates with thromboxane A 2 generation, including potential nonplatelet sources not readily affected by aspirin, are poorly understood. METHODS: We investigated 2655 FHS (Framingham Heart Study) participants with measurements of urinary thromboxane B 2 metabolites normalized for renal function (TXB 2 -M GFR ). Life’s Essential 8 (LE8) score was constructed from 8 modifiable factors. We additionally examined erythrocyte omega-3 fatty acids and omega-6 fatty acid levels, namely, eicosapentaenoic acid, docosahexaenoic acid, and arachidonic acid. In a subset of participants, objective measurements of vascular stiffness and adiposity were obtained. We related these factors to TXB 2 -M GFR using linear models, adjusting for age, sex, and aspirin use. We also explored the association of LE8 or omega-3 fatty acids with total CVD or heart failure stratified by TXB 2 -M GFR . RESULTS: Both total LE8 score ( P P 2 -M GFR . Higher omega-3 fatty acids (eicosapentaenoic acid+docosahexaenoic acid) and lower arachidonic acid were associated with lower TXB 2 -M GFR ( P 2 -M GFR was related to greater waist circumference, computed tomography–measured visceral adipose tissue, and hepatic steatosis ( P P 2 -M GFR and low LE8 displayed an over 5-fold higher risk of heart failure (hazard ratio, 5.07 [95% CI, 3.26–7.89]) and 2.5-fold higher risk of CVD (hazard ratio, 2.74 [95% CI, 2.04–3.68]) compared with participants with low TXB 2 -M GFR and high LE8. CONCLUSIONS: Our findings suggest several modifiable factors that may impact systemic thromboxane A 2 generation. Higher systemic thromboxane A 2 generation also appears to modulate the association of lifestyle measures (as assessed by LE8 score) with CVD and heart failure.

  • Open Access

    Safety and Efficacy of Different Stent Strategies in Percutaneous Coronary Intervention

    by Waqas Ullah, Harigopal Sandhyavenu, Syeda Ramsha Zaidi, Mileydis Alonso, Muhammad Atif Khan, Irfan Ullah, Farah Yasmin, Aravind Reddy Polam, Salman Zahid, Arnav Kumar, et al.


  • Association of Systemic Thromboxane Generation With Risk of Developing Heart Failure

    by Jeffrey J. Rade, Shari S. Kronsberg, Thomas S. Kickler, Ramachandran S. Vasan, Vanessa Xanthakis, Matthew G. Nayor, Bruce A. Barton


  • Adjustment for Renal Function Improves the Prognostic Performance of Urinary Thromboxane Metabolites

    by Bruce A Barton, Shari S Kronsberg, Essa Hariri, Ramachandran S Vasan, Grace A Rade, Vanessa Xanthakis, Thomas S Kickler, Jeffrey J Rade

    Systemic thromboxane A2 generation, assessed by quantifying the concentration of stable thromboxane B2 metabolites (TXB2-M) in the urine adjusted for urinary creatinine, is strongly associated with mortality risk. We sought to define optimal TXB2-M cutpoints for aspirin users and nonusers and determine if adjusting TXB2-M for estimated glomerular filtration rate (eGFR) in addition to urinary creatinine improved mortality risk assessment. Urinary TXB2-M were measured by competitive ELISA in 1363 aspirin users and 1681 nonusers participating in the Framingham Heart Study. Cutpoints were determined for TXB2-M and TXB2-M/eGFR using log-rank statistics and used to assess mortality risk by Cox proportional hazard modeling and restricted mean survival time. Multivariable models were compared using the Akaike Information Criterion (AIC). A cohort of 105 aspirin users with heart failure was used for external validation. Optimized cutpoints of TXB2-M were 1291 and 5609 pg/mg creatinine and of TXB2-M/eGFR were 16.6 and 62.1 filtered prostanoid units (defined as pg·min/creatinine·mL·1.73 m2), for aspirin users and nonusers, respectively. TXB2-M/eGFR cutpoints provided more robust all-cause mortality risk discrimination than TXB2-M cutpoints, with a larger unadjusted hazard ratio (2.88 vs 2.16, AIC P < 0.0001) and greater differences in restricted mean survival time between exposure groups (1.46 vs 1.10 years), findings that were confirmed in the external validation cohort of aspirin users. TXB2-M/eGFR cutpoints also provided better cardiovascular/stroke mortality risk discrimination than TXB2-M cutpoints (unadjusted hazard ratio 3.31 vs 2.13, AIC P < 0.0001). Adjustment for eGFR strengthens the association of urinary TXB2-M with long-term mortality risk irrespective of aspirin use.


  • Nonplatelet thromboxane generation is associated with impaired cardiovascular performance and mortality in heart failure

    by Essa Hariri, Nikolaos Kakouros, David A. Bunsick, Stuart D. Russell, James O. Mudd, Katherine Laws, Mikhailia W. Lake, Jeffrey J. Rade

    Nonplatelet thromboxane generation, stimulated largely by oxidative stress, is a novel mortality risk factor in individuals with coronary artery disease. Though inversely associated with left ventricular ejection fraction (LVEF), a potential role in the pathobiology of heart failure (HF) remains poorly defined. Nonplatelet thromboxane generation and oxidative stress were assessed by measuring urine thromboxane-B2 metabolites (TXB2-M) and 8-isoPGF2α by ELISA in 105 subjects taking aspirin and undergoing right heart catheterization for evaluation of HF, valve disease, or after transplantation. Multivariable logistic regression and survival analyses were used to define associations of TXB2-M to invasive measures of cardiovascular performance and 4-year clinical outcomes. TXB2-M was elevated (>1,500 pg/mg creatinine) in 46% of subjects and correlated with HF severity by New York Heart Association (NYHA) functional class and brain natriuretic peptide level, modestly with LVEF, but not with HF etiology. There was no association of oxidative stress to HF type or etiology but a trend with NYHA functional class. Multiple invasive hemodynamic parameters independently associated with TXB2-M after adjustment for oxidative stress, age, sex, and race with pulmonary effective arterial elastance (Ea pulmonary), reflective of right ventricular afterload, being the most robust on hierarchical analysis. Similar to Ea pulmonary, elevated urinary TXB2-M is associated with increased risk of death (adjusted HR = 2.15, P = 0.037) and a combination of death, transplant, or mechanical support initiation (adjusted HR = 2.0, P = 0.042). Nonplatelet TXA2 thromboxane generation is independently associated with HF severity reflected by invasive measures of cardiovascular performance, particularly right ventricular afterload, and independently predicted long-term mortality risk. NEW & NOTEWORTHY Nonplatelet thromboxane generation in heart failure is independently associated with risk of death, transplant, or need for mechanical support. Measurement of urine thromboxane metabolites using a clinically available assay may be a useful surrogate for invasive measurement of cardiovascular hemodynamics and performance that could provide prognostic information and facilitate tailoring of therapy in patients with heart failure. Inhibiting thromboxane generation or its biological effects is a potential strategy for improving cardiovascular performance and outcomes in heart failure.


  • Association of Thromboxane Generation With Survival in Aspirin Users and Nonusers

    by Jeffrey J. Rade, Bruce A. Barton, Ramachandran S. Vasan, Shari S. Kronsberg, Vanessa Xanthakis, John F. Keaney, Naomi M. Hamburg, Nikolaos Kakouros, Thomas A. Kickler


  • SARS-CoV-2 Initiates Programmed Cell Death in Platelets

    by Milka Koupenova, Heather A. Corkrey, Olga Vitseva, Kahraman Tanriverdi, Mohan Somasundaran, Ping Liu, Shaukat Soofi, Rohan Bhandari, Matthew Godwin, Krishna Mohan Parsi, et al.

    Rationale: Coronavirus disease 2019 (COVID-19) is characterized by increased incidence of microthrombosis with hyperactive platelets sporadically containing viral RNA. It is unclear if SARS-CoV-2 (severe acute respiratory syndrome, corona virus-2) directly alters platelet activation or if these changes are a reaction to infection-mediated global inflammatory alterations. Importantly, the direct effect of SARS-CoV-2 on platelets has yet to be studied. Objective: To characterize the direct SARS-CoV-2–platelet interactions using in vitro studies with purified infectious virions and samples from infected patients. Methods and Results: Platelet RNA analyzed by ARTIC v3 sequencing for SARS-CoV-2 showed presence of fragmented viral genome in all patients with COVID-19. Immunofluorescent imaging of platelets from patients with COVID-19 confirmed presence of SARS-CoV-2 proteins, whereas there was no detection of viral RNA by real-time quantitative polymerase chain reaction. Transmission electron microscopy of platelets incubated with purified SARS-CoV-2 virions demonstrated rapid internalization and digestion leading to distinct morphological changes and resulted in a release of extracellular vesicles. Interactions between SARS-CoV-2 and platelets occurred with or without ACE (angiotensin-converting enzyme) 2 presence as measured by immunofluorescence. Transmission electron microscopy showed that SARS-CoV-2 virions became internalized when they were attached to microparticles, bypassing the need for ACE2. Enrichment analysis of platelet transcriptome from patients with acute COVID-19, compared with those with clinical thrombosis, suggested upregulation of pathways related to virally mediated cell death, specifically necroptosis and apoptosis. Platelets incubated with infectious virus appeared to undergo cell death in 30 minutes postincubation as assessed by transmission electron microscopy and platelets from patients with COVID-19 showed evidence of increased markers of apoptosis and necroptosis by Western blot. Immunofluorescence confirmed colocalization of SARS-CoV-2 with phospho-MLKL (mixed lineage kinase domain-like pseudokinase) and caspase 3 on nonpermeabilized platelets in vitro and in COVID-19 platelets. Conclusions: Platelets internalize SARS-CoV-2 virions, directly or attached to microparticles, and viral internalization leads to rapid digestion, programmed cell death, and extracellular vesicle release. During COVID-19, platelets mediate a rapid response to SARS-CoV-2 and this response can contribute to dysregulated immunity and thrombosis.


  • SYMPTOMATIC ANGINA IN A PATIENT WITH CORONARY ARTERY ANEURYSMS AND MULTIVESSEL CORONARY ARTERY DISEASE

    by Kedar Mahagaokar, Cecillia Wong, Leora Balsam, Jeffrey Rade, Matthew Parker

  • Evaluation of a Real-World In-Hospital Antiplatelet-Switching Strategy Following Coronary Interventions: The SWITCH Study

    by Antoine Soueid, Ibrahim Kassas, Jeffrey Rade, Nikolaos Kakouros

    Newer antiplatelet therapy agents are reliable and have a fast onset of action, but have significantly higher cost, leading to compliance concerns. We adopted and evaluated an acute agent-switching strategy, using prasugrel or ticagrelor for rapid and reliable periprocedural antiplatelet action, followed by a switch to generic clopidogrel. from Journal of Invasive Cardiology. DAPT dual-antiplatelet therapy platelet adenosine diphosphate P2Y12 receptor inhibitor